The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia

Phase 1 Unknown 28 enrolled Jiangsu HengRui Medicine Co., Ltd.

RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the study is to assess the pharmacodynamic properties of drug-drug of SHR4640 and Febuxostat interaction in patients with Hyperuricemia.

Timeline

Start: 2019-10-14
Primary completion: 2020-06-01
Completion: 2020-06-30

Publications

Wang C, Yu Q, Jiang X, Deng Y, Sun F, Li X, Tao Y, Lin P, Ma Y, Zhu Y, Li C, Cao Y. A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia. J Clin Pharmacol. 2023 Feb;63(2):239-249. doi: 10.1002/jcph.2159. Epub 2022 Oct 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Febuxostat	Small molecule	80 mg	Oral
Subject	SHR4640	Small molecule	10 mg	Oral

Indications

No indication recorded.